GlassScriptPhysician profile
Rommy Issa
NPI 1922427236
$2,265.82
in general payments reported to CMS, 2019-2025
23 companies · $218 in 2025
The $218 reported for 2025 was more than what 78% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $155 · 2021: $135 · 2022: $235 · 2023: $733 · 2024: $612 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $664.01 | 2020-2024 | Farxiga, Lokelma, Andexxa |
| Janssen Pharmaceuticals, INC | $545.14 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $153.28 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $150.32 | 2019-2025 | Camzyos, Eliquis |
| Alexion Pharmaceuticals, INC. | $99.90 | 2019-2023 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.99 | 2024-2025 | Xifaxan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $68.88 | 2023 | Lifevest |
| Aimmune Therapeutics, INC. | $66.13 | 2024-2025 | Vowst |
| Merck Sharp & Dohme LLC | $64.42 | 2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.95 | 2024-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $40.11 | 2023-2024 | Inpefa |
| Melinta Therapeutics, LLC | $33.90 | 2019 | |
| Novo Nordisk INC | $33.36 | 2019-2022 | |
| Allergan, INC. | $30.79 | 2019 | |
| Abbvie INC. | $30.55 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $25.95 | 2022 | |
| Ucb, INC. | $22.90 | 2019 | |
| Amgen INC. | $22.32 | 2020 | |
| Portola Pharmaceuticals, LLC | $20.04 | 2019 | |
| Mallinckrodt Hospital Products INC. | $17.89 | 2023 | Terlivaz |
| Pfizer INC. | $17.80 | 2022 | |
| Abiomed | $16.90 | 2024 | Impella |
| Medtronic, INC. | $14.29 | 2024 | Kyphon Express II Kyphopak Tray |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rommy Issa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.